☰

cached image

Gavin MacBeath, PhD - Publications

Affiliations: 
Chemistry and Chemical Biology Harvard University, Cambridge, MA, United States 
Area:
Protein Systems
Website:
http://macbeath.hms.harvard.edu/
Tree Info Similar researchers PubMed Report error

68/231 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2019 Casaletto JB, Geddie ML, Abu-Yousif AO, Masson K, Fulgham A, Boudot A, Maiwald T, Kearns JD, Kohli N, Su S, Razlog M, Raue A, Kalra A, Håkansson M, Logan DT, ... ... MacBeath G, et al. MM-131, a bispecific anti-Met/EpCAM mAb, inhibits HGF-dependent and HGF-independent Met signaling through concurrent binding to EpCAM. Proceedings of the National Academy of Sciences of the United States of America. PMID 30898885 DOI: 10.1073/Pnas.1819085116  0.354
2018 Hass H, Masson K, Wohlgemuth S, Paragas V, Allen JE, Sevecka M, Pace E, Timmer J, Stelling J, MacBeath G, Schoeberl B, Raue A. Abstract 1312: Predicting ligand-dependent tumors from multi-dimensional signaling features Cancer Research. 78: 1312-1312. DOI: 10.1158/1538-7445.Am2018-1312  0.366
2017 Mathews S, Finn G, Kudla AJ, Rimkunas V, Laivins P, MacBeath G, Czibere A, Baum J. Abstract A19: Identification of Heregulin (HRG) expression as a driver of a difficult-to-treat cancer phenotype and development of a companion diagnostic for the HRG-ErbB3 targeting drug seribantumab Clinical Cancer Research. 23. DOI: 10.1158/1557-3265.Pmccavuln16-A19  0.301
2017 Finn G, Zhang H, Blois A, Mathews s, Kudla A, Baum J, Cieslewicz M, macbeath g, Adiwijaya B, Czibere A. Abstract A14: A randomized trial of exemestane +/- seribantumab (MM-121) in postmenopausal women with locally advanced or metastatic ER/PR+ HER2- breast cancer: Final analysis and extended subgroup analysis Clinical Cancer Research. 23. DOI: 10.1158/1557-3265.Pmccavuln16-A14  0.308
2015 Curley MD, Sabnis GJ, Wille L, Adiwijaya BS, Garcia G, Moyo V, Kazi AA, Brodie A, MacBeath G. Seribantumab, an anti-ERBB3 antibody, delays the onset of resistance and restores sensitivity to letrozole in an estrogen receptor-positive breast cancer model. Molecular Cancer Therapeutics. PMID 26310543 DOI: 10.1158/1535-7163.Mct-15-0169  0.312
2015 Yarar D, Lahdenranta J, Kubasek W, Nielsen UB, MacBeath G. Heregulin-ErbB3-Driven Tumor Growth Persists in PI3 Kinase Mutant Cancer Cells. Molecular Cancer Therapeutics. PMID 26116360 DOI: 10.1158/1535-7163.Mct-15-0075  0.363
2015 Masson K, Grantcharova V, Burenkova O, Wainszelbaum M, Iadevaia S, Adams S, Raue A, Czibere A, Schoeberl B, MacBeath G. Abstract LB-243: The ErbB3-targeting antibody MM-121 (seribantumab) reverses heregulin-driven resistance to multiple chemotherapies on tumor cell growth Cancer Research. 75. DOI: 10.1158/1538-7445.Am2015-Lb-243  0.327
2015 Abu-Yousif AO, Casaletto JB, Masson K, Fulgham A, Geddie M, Schoeberl B, Nielsen U, MacBeath G. Abstract 1690: Mechanistic characterization of MM-131, a bispecific antibody that blocks c-Met signaling through concurrent targeting of EpCAM Cancer Research. 75: 1690-1690. DOI: 10.1158/1538-7445.Am2015-1690  0.328
2015 Wainszelbaum MJ, Fessler J, Lahdenranta J, Burenkova O, Gerami-Moayed N, Hashambhoy-Ramsay Y, Rimkunas V, MacBeath G. Abstract LB-C25: Inhibition of ERBB3 with MM-121, IGF1-R with MM-141 or Met with MM-131 increases the activity of EGFR inhibitor MM-151 in colorectal cancer models expressing multiple resistance ligands Molecular Cancer Therapeutics. 14. DOI: 10.1158/1535-7163.Targ-15-Lb-C25  0.334
2014 Gujral TS, Chan M, Peshkin L, Sorger PK, Kirschner MW, MacBeath G. A noncanonical Frizzled2 pathway regulates epithelial-mesenchymal transition and metastasis. Cell. 159: 844-56. PMID 25417160 DOI: 10.1016/J.Cell.2014.10.032  0.736
2014 AlQuraishi M, Koytiger G, Jenney A, MacBeath G, Sorger PK. A multiscale statistical mechanical framework integrates biophysical and genomic data to assemble cancer networks. Nature Genetics. 46: 1363-71. PMID 25362484 DOI: 10.1038/Ng.3138  0.771
2014 Yi CR, Allen JE, Russo B, Lee SY, Heindl JE, Baxt LA, Herrera BB, Kahoud E, MacBeath G, Goldberg MB. Systematic analysis of bacterial effector-postsynaptic density 95/disc large/zonula occludens-1 (PDZ) domain interactions demonstrates Shigella OspE protein promotes protein kinase C activation via PDLIM proteins. The Journal of Biological Chemistry. 289: 30101-13. PMID 25124035 DOI: 10.1074/Jbc.M114.595868  0.516
2014 Jiang N, Wang D, Hu Z, Shin HJ, Qian G, Rahman MA, Zhang H, Amin AR, Nannapaneni S, Wang X, Chen Z, Garcia G, MacBeath G, Shin DM, Khuri FR, et al. Combination of anti-HER3 antibody MM-121/SAR256212 and cetuximab inhibits tumor growth in preclinical models of head and neck squamous cell carcinoma. Molecular Cancer Therapeutics. 13: 1826-36. PMID 24748655 DOI: 10.1158/1535-7163.Mct-13-1093  0.315
2013 Onsum MD, Geretti E, Paragas V, Kudla AJ, Moulis SP, Luus L, Wickham TJ, McDonagh CF, Macbeath G, Hendriks BS. Single-cell quantitative HER2 measurement identifies heterogeneity and distinct subgroups within traditionally defined HER2-positive patients. The American Journal of Pathology. 183: 1446-60. PMID 24035511 DOI: 10.1016/J.Ajpath.2013.07.015  0.348
2013 Wagner JP, Wolf-Yadlin A, Sevecka M, Grenier JK, Root DE, Lauffenburger DA, MacBeath G. Receptor tyrosine kinases fall into distinct classes based on their inferred signaling networks. Science Signaling. 6: ra58. PMID 23861540 DOI: 10.4172/2153-0602.C1.003  0.368
2013 Gujral TS, Karp ES, Chan M, Chang BH, MacBeath G. Family-wide investigation of PDZ domain-mediated protein-protein interactions implicates β-catenin in maintaining the integrity of tight junctions. Chemistry & Biology. 20: 816-27. PMID 23790492 DOI: 10.1016/J.Chembiol.2013.04.021  0.808
2013 Kaushansky A, Ye AS, Austin LS, Mikolajczak SA, Vaughan AM, Camargo N, Metzger PG, Douglass AN, MacBeath G, Kappe SH. Suppression of host p53 is critical for Plasmodium liver-stage infection. Cell Reports. 3: 630-7. PMID 23478020 DOI: 10.1016/J.Celrep.2013.02.010  0.736
2013 Koytiger G, Kaushansky A, Gordus A, Rush J, Sorger PK, MacBeath G. Phosphotyrosine signaling proteins that drive oncogenesis tend to be highly interconnected. Molecular & Cellular Proteomics : McP. 12: 1204-13. PMID 23358503 DOI: 10.1074/Mcp.M112.025858  0.805
2013 Gujral TS, Karp RL, Finski A, Chan M, Schwartz PE, MacBeath G, Sorger P. Profiling phospho-signaling networks in breast cancer using reverse-phase protein arrays. Oncogene. 32: 3470-6. PMID 22945653 DOI: 10.1038/Onc.2012.378  0.733
2013 Jiang N, Wang D, Hu Z, Rahman AM, Zhang H, Amin RA, Wang X, Chen Z, Dong SM, Garcia G, MacBeath G, Ma J, Khuri FR, Saba NF, Chen GZ. Abstract LB-79: Combined treatment with HER3 antibody MM-121/SAR 256212 and EGFR antibody cetuximab in pre-clinical models of head and neck cancer. Cancer Research. 73. DOI: 10.1158/1538-7445.Am2013-Lb-79  0.301
2013 Wainszelbaum MJ, Sevecka MS, Burenkova O, Garcia G, Kubasek W, MacBeath G. Abstract 5464: In-vitro studies of MM-121/SAR 256212, an anti-ErbB-3 antibody, in combination with erlotinib in EGFR-wild-type NSCLC. Cancer Research. 73: 5464-5464. DOI: 10.1158/1538-7445.Am2013-5464  0.305
2012 Lee MJ, Ye AS, Gardino AK, Heijink AM, Sorger PK, MacBeath G, Yaffe MB. Sequential application of anticancer drugs enhances cell death by rewiring apoptotic signaling networks. Cell. 149: 780-94. PMID 22579283 DOI: 10.1016/J.Cell.2012.03.031  0.77
2012 Beyer EM, MacBeath G. Cross-talk between receptor tyrosine kinase and tumor necrosis factor-α signaling networks regulates apoptosis but not proliferation. Molecular & Cellular Proteomics : McP. 11: M111.013292. PMID 22323825 DOI: 10.1074/Mcp.M111.013292  0.722
2012 Luckert K, Gujral TS, Chan M, Sevecka M, Joos TO, Sorger PK, Macbeath G, Pötz O. A dual array-based approach to assess the abundance and posttranslational modification state of signaling proteins. Science Signaling. 5: pl1. PMID 22234610 DOI: 10.1126/Scisignal.2002372  0.733
2012 Onsum M, Yarar D, Paragas V, Zhang B, Nguyen S, Schoeberl B, McDonagh C, MacBeath G, Nielsen U. Abstract 4945: Targeting ErbB3-addicted cancers across the HER2 spectrum Cancer Research. 72: 4945-4945. DOI: 10.1158/1538-7445.Am2012-4945  0.369
2012 Geretti E, Paragas V, Onsum M, Kudla A, Moulis S, Luus L, Wickham T, McDonagh C, MacBeath G, Hendriks B. Abstract P1-07-03: Quantification of HER2 expression at the single cell level and HER2 intratumoral heterogeneity of breast cancer tissue samples using automated image analysis Cancer Research. 72. DOI: 10.1158/0008-5472.Sabcs12-P1-07-03  0.33
2011 Chang BH, Gujral TS, Karp ES, BuKhalid R, Grantcharova VP, MacBeath G. A systematic family-wide investigation reveals that ~30% of mammalian PDZ domains engage in PDZ-PDZ interactions. Chemistry & Biology. 18: 1143-52. PMID 21944753 DOI: 10.1016/J.Chembiol.2011.06.013  0.8
2011 Jung AS, Kaushansky A, Macbeath G, Kaushansky K. Tensin2 is a novel mediator in thrombopoietin (TPO)-induced cellular proliferation by promoting Akt signaling. Cell Cycle (Georgetown, Tex.). 10: 1838-44. PMID 21527831 DOI: 10.4161/Cc.10.11.15776  0.752
2011 Knickerbocker T, MacBeath G. Detecting and quantifying multiple proteins in clinical samples in high-throughput using antibody microarrays. Methods in Molecular Biology (Clifton, N.J.). 723: 3-13. PMID 21370055 DOI: 10.1007/978-1-61779-043-0_1  0.766
2011 Sevecka M, Wolf-Yadlin A, MacBeath G. Lysate microarrays enable high-throughput, quantitative investigations of cellular signaling. Molecular & Cellular Proteomics : McP. 10: M110.005363. PMID 21296872 DOI: 10.1074/Mcp.M110.005363  0.393
2011 Krall JA, Beyer EM, MacBeath G. High- and low-affinity epidermal growth factor receptor-ligand interactions activate distinct signaling pathways. Plos One. 6: e15945. PMID 21264347 DOI: 10.1371/Journal.Pone.0015945  0.792
2011 Oyama SK, Paragas V, Adams S, Luus L, Huhalov A, Kudla AJ, Overland R, Nielsen UB, Niyikiza C, McDonagh CF, MacBeath G. Abstract 654: MM-111, an ErbB2/ErbB3 bispecific antibody, effectively combines with lapatinib to inhibit growth of ErbB2-overexpressing tumor cells Cancer Research. 71: 654-654. DOI: 10.1158/1538-7445.Am2011-654  0.317
2010 Boettcher JP, Kirchner M, Churin Y, Kaushansky A, Pompaiah M, Thorn H, Brinkmann V, Macbeath G, Meyer TF. Tyrosine-phosphorylated caveolin-1 blocks bacterial uptake by inducing Vav2-RhoA-mediated cytoskeletal rearrangements. Plos Biology. 8. PMID 20808760 DOI: 10.1371/Journal.Pbio.1000457  0.68
2010 Mehlitz A, Banhart S, Mäurer AP, Kaushansky A, Gordus AG, Zielecki J, Macbeath G, Meyer TF. Tarp regulates early Chlamydia-induced host cell survival through interactions with the human adaptor protein SHC1. The Journal of Cell Biology. 190: 143-57. PMID 20624904 DOI: 10.1083/Jcb.200909095  0.816
2010 Gujral TS, MacBeath G. A system-wide investigation of the dynamics of Wnt signaling reveals novel phases of transcriptional regulation. Plos One. 5: e10024. PMID 20383323 DOI: 10.1371/Journal.Pone.0010024  0.697
2010 Kaushansky A, Allen JE, Gordus A, Stiffler MA, Karp ES, Chang BH, MacBeath G. Quantifying protein-protein interactions in high throughput using protein domain microarrays. Nature Protocols. 5: 773-90. PMID 20360771 DOI: 10.1038/Nprot.2010.36  0.784
2010 Shalek AK, Robinson JT, Karp ES, Lee JS, Ahn DR, Yoon MH, Sutton A, Jorgolli M, Gertner RS, Gujral TS, MacBeath G, Yang EG, Park H. Vertical silicon nanowires as a universal platform for delivering biomolecules into living cells. Proceedings of the National Academy of Sciences of the United States of America. 107: 1870-5. PMID 20080678 DOI: 10.1073/Pnas.0909350107  0.773
2009 Gujral TS, MacBeath G. Emerging miniaturized proteomic technologies to study cell signaling in clinical samples. Science Signaling. 2: pe65. PMID 19843955 DOI: 10.1126/Scisignal.293Pe64  0.699
2009 Wolf-Yadlin A, Sevecka M, MacBeath G. Dissecting protein function and signaling using protein microarrays. Current Opinion in Chemical Biology. 13: 398-405. PMID 19660979 DOI: 10.1016/J.Cbpa.2009.06.027  0.44
2009 Gordus A, Krall JA, Beyer EM, Kaushansky A, Wolf-Yadlin A, Sevecka M, Chang BH, Rush J, MacBeath G. Linear combinations of docking affinities explain quantitative differences in RTK signaling. Molecular Systems Biology. 5: 235. PMID 19156127 DOI: 10.1038/Msb.2008.72  0.779
2008 Kaushansky A, Gordus A, Budnik BA, Lane WS, Rush J, MacBeath G. System-wide investigation of ErbB4 reveals 19 sites of Tyr phosphorylation that are unusually selective in their recruitment properties. Chemistry & Biology. 15: 808-17. PMID 18721752 DOI: 10.1016/J.Chembiol.2008.07.006  0.815
2008 Chen JR, Chang BH, Allen JE, Stiffler MA, MacBeath G. Predicting PDZ domain-peptide interactions from primary sequences. Nature Biotechnology. 26: 1041-5. PMID 18711339 DOI: 10.1038/Nbt.1489  0.797
2008 Kaushansky A, Gordus A, Chang B, Rush J, MacBeath G. A quantitative study of the recruitment potential of all intracellular tyrosine residues on EGFR, FGFR1 and IGF1R. Molecular Biosystems. 4: 643-53. PMID 18493663 DOI: 10.1039/B801018H  0.818
2008 Chen JR, Chang BH, Allen JE, Stiffler MA, MacBeath G. Predicting PDZ domain-peptide interactions from primary sequences (Nature Biotechnology (2008) 26, (1041-1045)) Nature Biotechnology. 26: 1193. DOI: 10.1038/Nbt1008-1193C  0.77
2007 Macbeath G. Protein arrays: sandwich approach for analyzing complex solutions. Csh Protocols. 2007: pdb.prot4633. PMID 21357035 DOI: 10.1101/Pdb.Prot4633  0.395
2007 Macbeath G. Protein arrays: probing the array and detecting radioactive spots for kinase-substrate interactions. Csh Protocols. 2007: pdb.prot4632. PMID 21357034 DOI: 10.1101/Pdb.Prot4632  0.371
2007 Macbeath G. Protein arrays: labeling the compounds and probing the array for protein-small molecule interactions. Csh Protocols. 2007: pdb.prot4631. PMID 21357033 DOI: 10.1101/Pdb.Prot4631  0.339
2007 Macbeath G. Protein arrays: labeling the protein and probing the array for protein-protein interactions. Csh Protocols. 2007: pdb.prot4630. PMID 21357032 DOI: 10.1101/Pdb.Prot4630  0.413
2007 Macbeath G. Protein arrays: preparation of microscope slides. Csh Protocols. 2007: pdb.prot4629. PMID 21357031 DOI: 10.1101/Pdb.Prot4629  0.352
2007 Stiffler MA, Chen JR, Grantcharova VP, Lei Y, Fuchs D, Allen JE, Zaslavskaia LA, MacBeath G. PDZ domain binding selectivity is optimized across the mouse proteome. Science (New York, N.Y.). 317: 364-9. PMID 17641200 DOI: 10.1126/Science.1144592  0.816
2007 Knickerbocker T, Chen JR, Thadhani R, MacBeath G. An integrated approach to prognosis using protein microarrays and nonparametric methods. Molecular Systems Biology. 3: 123. PMID 17593911 DOI: 10.1038/Msb4100167  0.761
2006 Albeck JG, MacBeath G, White FM, Sorger PK, Lauffenburger DA, Gaudet S. Collecting and organizing systematic sets of protein data. Nature Reviews. Molecular Cell Biology. 7: 803-12. PMID 17057751 DOI: 10.1038/Nrm2042  0.313
2006 Gordus A, MacBeath G. Circumventing the problems caused by protein diversity in microarrays: implications for protein interaction networks. Journal of the American Chemical Society. 128: 13668-9. PMID 17044677 DOI: 10.1021/Ja065381G  0.779
2006 Sevecka M, MacBeath G. State-based discovery: a multidimensional screen for small-molecule modulators of EGF signaling. Nature Methods. 3: 825-31. PMID 16990815 DOI: 10.1038/Nmeth931  0.368
2006 Stiffler MA, Grantcharova VP, Sevecka M, MacBeath G. Uncovering quantitative protein interaction networks for mouse PDZ domains using protein microarrays. Journal of the American Chemical Society. 128: 5913-22. PMID 16637659 DOI: 10.1021/Ja060943H  0.823
2006 Jones RB, Gordus A, Krall JA, MacBeath G. A quantitative protein interaction network for the ErbB receptors using protein microarrays. Nature. 439: 168-74. PMID 16273093 DOI: 10.1038/Nature04177  0.822
2003 Nielsen UB, Cardone MH, Sinskey AJ, MacBeath G, Sorger PK. Profiling receptor tyrosine kinase activation by using Ab microarrays. Proceedings of the National Academy of Sciences of the United States of America. 100: 9330-5. PMID 12876202 DOI: 10.1073/Pnas.1633513100  0.46
2002 MacBeath G. Protein microarrays and proteomics. Nature Genetics. 32: 526-32. PMID 12454649 DOI: 10.1038/Ng1037  0.391
2001 MacBeath G. Proteomics comes to the surface. Nature Biotechnology. 19: 828-9. PMID 11533639 DOI: 10.1038/Nbt0901-828  0.341
2000 MacBeath G, Schreiber SL. Printing proteins as microarrays for high-throughput function determination. Science (New York, N.Y.). 289: 1760-3. PMID 10976071 DOI: 10.1126/Science.289.5485.1760  0.564
1999 MacBeath G, Koehler AN, Schreiber SL. Printing small molecules as microarrays and detecting protein-ligand interactions en masse [19] Journal of the American Chemical Society. 121: 7967-7968. DOI: 10.1021/Ja991083Q  0.487
1998 MacBeath G, Kast P, Hilvert D. Probing enzyme quaternary structure by combinatorial mutagenesis and selection. Protein Science : a Publication of the Protein Society. 7: 1757-67. PMID 10082372 DOI: 10.1002/Pro.5560070810  0.551
1998 MacBeath G, Kast P, Hilvert D. A small, thermostable, and monofunctional chorismate mutase from the archaeon Methanococcus jannaschii. Biochemistry. 37: 10062-73. PMID 9665711 DOI: 10.1021/Bi980449T  0.502
1998 MacBeath G, Kast P. UGA read-through artifacts--when popular gene expression systems need a pATCH. Biotechniques. 24: 789-94. PMID 9591128 DOI: 10.2144/98245St02  0.335
1998 MacBeath G, Kast P, Hilvert D. Exploring sequence constraints on an interhelical turn using in vivo selection for catalytic activity. Protein Science : a Publication of the Protein Society. 7: 325-35. PMID 9521108 DOI: 10.1002/Pro.5560070212  0.562
1998 MacBeath G, Kast P, Hilvert D. Redesigning enzyme topology by directed evolution. Science (New York, N.Y.). 279: 1958-61. PMID 9506949 DOI: 10.1126/Science.279.5358.1958  0.571
1996 MacBeath G, Hilvert D. Hydrolytic antibodies: variations on a theme. Chemistry & Biology. 3: 433-45. PMID 8807874 DOI: 10.1016/S1074-5521(96)90091-5  0.487
1994 MacBeath G, Hilvert D. Monitoring Catalytic Activity by Immunoassay: Implications for Screening Journal of the American Chemical Society. 116: 6101-6106. DOI: 10.1021/Ja00093A006  0.472
Low-probability matches (unlikely to be authored by this person)
2011 Zhang B, Huhalov A, Burenkova O, Adams S, Nguyen S, Overland R, Kudla AJ, Nielsen UB, Niyikiza C, McDonagh CF, MacBeath G. Abstract 655: Combination of MM-111, an ErbB2/ErbB3 bispecific antibody, with endocrine therapies as an effective strategy for treatment of ER+/HER2+ breast cancer Cancer Research. 71: 655-655. DOI: 10.1158/1538-7445.Am2011-655  0.299
2013 Curley MD, Sabnis G, Wille L, Garcia G, Moyo V, Kazi A, MacBeath G, Brodie A. Abstract 1072: MM-121/SAR256212, an anti-ErbB3 antibody, restores sensitivity to letrozole and delays the onset of resistance in an ER+ breast cancer model. Cancer Research. 73: 1072-1072. DOI: 10.1158/1538-7445.Am2013-1072  0.294
2016 Liu JF, Ray-Coquard I, Selle F, Poveda AM, Cibula D, Hirte H, Hilpert F, Raspagliesi F, Gladieff L, Harter P, Siena S, Del Campo JM, Tabah-Fisch I, Pearlberg J, Moyo V, ... ... MacBeath G, et al. Randomized Phase II Trial of Seribantumab in Combination With Paclitaxel in Patients With Advanced Platinum-Resistant or -Refractory Ovarian Cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 34: 4345-4353. PMID 27998236 DOI: 10.1200/Jco.2016.67.1891  0.292
2001 MacBeath G. Chemical genomics: what will it take and who gets to play? Genome Biology. 2: COMMENT2005. PMID 11423004 DOI: 10.1186/Gb-2001-2-6-Comment2005  0.284
2014 Macbeath G, Adiwijaya B, Liu J, Sequist L, Pujade-Lauraine E, Higgins M, Tabah-Fisch I, Pearlberg J, Moyo V, Kubasek W, Nering R, Czibere A. A Meta-Analysis of Biomarkers in Three Randomized, Phase 2 Studies of Mm-121, a Ligand-Blocking Anti-Erbb3 Antibody, in Patients with Ovarian, Lung, and Breast Cancers Annals of Oncology. 25: iv82. DOI: 10.1093/Annonc/Mdu326.79  0.281
2015 Holmes FA, McIntyre KJ, Krop IE, Osborne CR, Smith JW, Modiano MR, Gupta M, Downey LB, Nanda R, Saleh MN, Young JR, Horgan KE, Kubasek W, MacBeath G, Danso MA, et al. Abstract P3-11-03: A randomized, phase 2 trial of preoperative MM-121 with paclitaxel in triple negative (TN) and hormone receptor (HR) positive, HER2-negative breast cancer Cancer Research. 75. DOI: 10.1158/1538-7445.Sabcs14-P3-11-03  0.28
2016 Bazdar-Vinovrski B, Wainszelbaum M, MacBeath G. A phase 1 biomarker-directed multi-arm study evaluating the co-administration of MM-151 with MM-121, MM-141, or trametinib in EGFR-driven cancers. Journal of Clinical Oncology. 34: TPS11619-TPS11619. DOI: 10.1200/Jco.2016.34.15_Suppl.Tps11619  0.28
2017 Schelker M, Feau S, Du J, Ranu N, Klipp E, MacBeath G, Schoeberl B, Raue A. Estimation of immune cell content in tumour tissue using single-cell RNA-seq data. Nature Communications. 8: 2032. PMID 29230012 DOI: 10.1038/S41467-017-02289-3  0.277
2015 Qian G, Jiang N, Wang D, Newman S, Kim S, Chen Z, Garcia G, MacBeath G, Shin DM, Khuri FR, Chen ZG, Saba NF. Heregulin and HER3 are prognostic biomarkers in oropharyngeal squamous cell carcinoma. Cancer. PMID 26195293 DOI: 10.1002/Cncr.29549  0.273
2014 Higgins MJ, Doyle C, Paepke S, Azaro A, Martin M, Semiglazov V, Smirnova I, Krasnozhon D, Manikhas A, Harb WA, Panasci LC, Pearlberg J, MacBeath G, Nering R, Goss PE, et al. A randomized, double-blind phase II trial of exemestane plus MM-121 (a monoclonal antibody targeting ErbB3) or placebo in postmenopausal women with locally advanced or metastatic ER+/PR+, HER2-negative breast cancer. Journal of Clinical Oncology. 32: 587-587. DOI: 10.1200/Jco.2014.32.15_Suppl.587  0.27
2014 Sequist LV, Lopez-Chavez A, Doebele RC, Gray JE, Harb WA, Modiano MR, Jackman DM, Baggstrom MQ, Atmaca A, Felip E, Provencio M, Cobo M, Kripas CJ, MacBeath G, Czibere AG, et al. A randomized phase 2 trial of MM-121, a fully human monoclonal antibody targeting ErbB3, in combination with erlotinib in EGFR wild-type NSCLC patients. Journal of Clinical Oncology. 32: 8051-8051. DOI: 10.1200/Jco.2014.32.15_Suppl.8051  0.268
2017 Schoeberl B, Kudla A, Masson K, Kalra A, Curley M, Finn G, Pace E, Harms B, Kim J, Kearns J, Fulgham A, Burenkova O, Grantcharova V, Yarar D, Paragas V, ... ... MacBeath G, et al. Systems biology driving drug development: from design to the clinical testing of the anti-ErbB3 antibody seribantumab (MM-121). Npj Systems Biology and Applications. 3: 16034. PMID 28725482 DOI: 10.1038/npjsba.2016.34  0.262
2011 Denlinger CS, Keedy VL, Cleary JM, Kubasek W, Onsum M, Moulis S, Garcia G, Schoeberl B, MacBeath G, Nering R, Murray J, Moyo V, Wong K, Shapiro G. Abstract LB-410: Phase I dose escalation study of MM-121, a fully human monoclonal antibody to ErbB3, in patients with advanced solid tumors Cancer Research. 71. DOI: 10.1158/1538-7445.Am2011-Lb-410  0.261
2014 Liu J, Ray-Coquard IL, Selle F, Poveda A, Cibula D, Hirte HW, Raspagliesi F, Gladieff L, Harter P, Schiavetto I, Tabah-Fisch IM, MacBeath G, Czibere AG, Naumann RW, Coleman RL, et al. A phase II randomized open-label study of MM-121, a fully human monoclonal antibody targeting ErbB3, in combination with weekly paclitaxel versus weekly paclitaxel in patients with platinum-resistant/refractory ovarian cancers. Journal of Clinical Oncology. 32: 5519-5519. DOI: 10.1200/Jco.2014.32.15_Suppl.5519  0.259
2014 Saba NF, Qian G, Ning J, Kim S, Chen Z, Garcia G, MacBeath G, Shin DM, Khuri FR, Chen ZG. Expressions of EGFR, HER2, and HER3 and their correlations with clinical characteristics in oropharyngeal squamous cell carcinoma (OPSCC). Journal of Clinical Oncology. 32: 6068-6068. DOI: 10.1200/Jco.2014.32.15_Suppl.6068  0.244
2016 Cleary JM, McRee AJ, Shapiro GI, Tolaney SM, O'Neil BH, Kearns JD, Mathews S, Nering R, MacBeath G, Czibere A, Sharma S, Korn WM. A phase 1 study combining the HER3 antibody seribantumab (MM-121) and cetuximab with and without irinotecan. Investigational New Drugs. PMID 27853996 DOI: 10.1007/S10637-016-0399-7  0.236
2009 MacBeath G, Saghatelian A. The promise and challenge of '-omic' approaches. Current Opinion in Chemical Biology. 13: 501-2. PMID 19853495 DOI: 10.1016/J.Cbpa.2009.10.008  0.225
2017 Schelker M, Du J, Feau S, Klipp E, Schoeberl B, MacBeath G, Raue A. Abstract 559: Estimation of immune cell content in bulk tumour tissue using reference profiles from single-cell RNA-seq data Cancer Research. 77: 559-559. DOI: 10.1158/1538-7445.Am2017-559  0.214
2017 Hass H, Masson K, Wohlgemuth S, Paragas V, Allen JE, Sevecka M, Pace E, Timmer J, Stelling J, MacBeath G, Schoeberl B, Raue A. Predicting ligand-dependent tumors from multi-dimensional signaling features. Npj Systems Biology and Applications. 3: 27. PMID 28944080 DOI: 10.1038/s41540-017-0030-3  0.2
1994 LéJohn HB, Cameron LE, Yang B, MacBeath G, Barker DS, Williams SA. Cloning and analysis of a constitutive heat shock (cognate) protein 70 gene inducible by L-glutamine. The Journal of Biological Chemistry. 269: 4513-22. PMID 8308021  0.199
2020 Ferretti AP, Kula T, Wang Y, Nguyen DMV, Weinheimer A, Dunlap GS, Xu Q, Nabilsi N, Perullo CR, Cristofaro AW, Whitton HJ, Virbasius A, Olivier KJ, Buckner LR, Alistar AT, ... ... MacBeath G, et al. Unbiased Screens Show CD8 T Cells of COVID-19 Patients Recognize Shared Epitopes in SARS-CoV-2 that Largely Reside outside the Spike Protein. Immunity. PMID 33128877 DOI: 10.1016/j.immuni.2020.10.006  0.153
2014 Harms B, Lugovskoy A, Abu-Yousif A, Fulgham A, Geddie M, Su S, Kohli N, Johnson B, Masson K, Nielsen U, Schoeberl B, MacBeath G. 438 MM-131: A bispecific antibody that inhibits c-Met signaling through avid binding to the EpCAM tumor antigen European Journal of Cancer. 50: 144. DOI: 10.1016/S0959-8049(14)70564-7  0.147
2014 Harms B, Lugovskoy A, Abu-Yousif A, Fulgham A, Geddie M, Su S, Kohli N, Johnson B, Masson K, Nielsen U, Schoeberl B, MacBeath G. 438 MM-131: A bispecific antibody that inhibits c-Met signaling through avid binding to the EpCAM tumor antigen European Journal of Cancer. 50: 144. DOI: 10.1016/S0959-8049(14)70564-7  0.147
2014 Harms B, Lugovskoy A, Abu-Yousif A, Fulgham A, Geddie M, Su S, Kohli N, Johnson B, Masson K, Nielsen U, Schoeberl B, MacBeath G. 438 MM-131: A bispecific antibody that inhibits c-Met signaling through avid binding to the EpCAM tumor antigen European Journal of Cancer. 50: 144. DOI: 10.1016/S0959-8049(14)70564-7  0.147
2014 Harms B, Lugovskoy A, Abu-Yousif A, Fulgham A, Geddie M, Su S, Kohli N, Johnson B, Masson K, Nielsen U, Schoeberl B, MacBeath G. 438 MM-131: A bispecific antibody that inhibits c-Met signaling through avid binding to the EpCAM tumor antigen European Journal of Cancer. 50: 144. DOI: 10.1016/S0959-8049(14)70564-7  0.147
2014 Harms B, Lugovskoy A, Abu-Yousif A, Fulgham A, Geddie M, Su S, Kohli N, Johnson B, Masson K, Nielsen U, Schoeberl B, MacBeath G. 438 MM-131: A bispecific antibody that inhibits c-Met signaling through avid binding to the EpCAM tumor antigen European Journal of Cancer. 50: 144. DOI: 10.1016/S0959-8049(14)70564-7  0.147
2014 Harms B, Lugovskoy A, Abu-Yousif A, Fulgham A, Geddie M, Su S, Kohli N, Johnson B, Masson K, Nielsen U, Schoeberl B, MacBeath G. 438 MM-131: A bispecific antibody that inhibits c-Met signaling through avid binding to the EpCAM tumor antigen European Journal of Cancer. 50: 144. DOI: 10.1016/S0959-8049(14)70564-7  0.147
2014 Harms B, Lugovskoy A, Abu-Yousif A, Fulgham A, Geddie M, Su S, Kohli N, Johnson B, Masson K, Nielsen U, Schoeberl B, MacBeath G. 438 MM-131: A bispecific antibody that inhibits c-Met signaling through avid binding to the EpCAM tumor antigen European Journal of Cancer. 50: 144. DOI: 10.1016/S0959-8049(14)70564-7  0.147
2014 Harms B, Lugovskoy A, Abu-Yousif A, Fulgham A, Geddie M, Su S, Kohli N, Johnson B, Masson K, Nielsen U, Schoeberl B, MacBeath G. 438 MM-131: A bispecific antibody that inhibits c-Met signaling through avid binding to the EpCAM tumor antigen European Journal of Cancer. 50: 144. DOI: 10.1016/S0959-8049(14)70564-7  0.147
2014 Harms B, Lugovskoy A, Abu-Yousif A, Fulgham A, Geddie M, Su S, Kohli N, Johnson B, Masson K, Nielsen U, Schoeberl B, MacBeath G. 438 MM-131: A bispecific antibody that inhibits c-Met signaling through avid binding to the EpCAM tumor antigen European Journal of Cancer. 50: 144. DOI: 10.1016/S0959-8049(14)70564-7  0.147
2014 Harms B, Lugovskoy A, Abu-Yousif A, Fulgham A, Geddie M, Su S, Kohli N, Johnson B, Masson K, Nielsen U, Schoeberl B, MacBeath G. 438 MM-131: A bispecific antibody that inhibits c-Met signaling through avid binding to the EpCAM tumor antigen European Journal of Cancer. 50: 144. DOI: 10.1016/S0959-8049(14)70564-7  0.147
2014 Harms B, Lugovskoy A, Abu-Yousif A, Fulgham A, Geddie M, Su S, Kohli N, Johnson B, Masson K, Nielsen U, Schoeberl B, MacBeath G. 438 MM-131: A bispecific antibody that inhibits c-Met signaling through avid binding to the EpCAM tumor antigen European Journal of Cancer. 50: 144. DOI: 10.1016/S0959-8049(14)70564-7  0.147
2014 Harms B, Lugovskoy A, Abu-Yousif A, Fulgham A, Geddie M, Su S, Kohli N, Johnson B, Masson K, Nielsen U, Schoeberl B, MacBeath G. 438 MM-131: A bispecific antibody that inhibits c-Met signaling through avid binding to the EpCAM tumor antigen European Journal of Cancer. 50: 144. DOI: 10.1016/S0959-8049(14)70564-7  0.147
2014 Harms B, Lugovskoy A, Abu-Yousif A, Fulgham A, Geddie M, Su S, Kohli N, Johnson B, Masson K, Nielsen U, Schoeberl B, MacBeath G. 438 MM-131: A bispecific antibody that inhibits c-Met signaling through avid binding to the EpCAM tumor antigen European Journal of Cancer. 50: 144. DOI: 10.1016/S0959-8049(14)70564-7  0.147
2014 Harms B, Lugovskoy A, Abu-Yousif A, Fulgham A, Geddie M, Su S, Kohli N, Johnson B, Masson K, Nielsen U, Schoeberl B, MacBeath G. 438 MM-131: A bispecific antibody that inhibits c-Met signaling through avid binding to the EpCAM tumor antigen European Journal of Cancer. 50: 144. DOI: 10.1016/S0959-8049(14)70564-7  0.147
2014 Harms B, Lugovskoy A, Abu-Yousif A, Fulgham A, Geddie M, Su S, Kohli N, Johnson B, Masson K, Nielsen U, Schoeberl B, MacBeath G. 438 MM-131: A bispecific antibody that inhibits c-Met signaling through avid binding to the EpCAM tumor antigen European Journal of Cancer. 50: 144. DOI: 10.1016/S0959-8049(14)70564-7  0.147
2014 Harms B, Lugovskoy A, Abu-Yousif A, Fulgham A, Geddie M, Su S, Kohli N, Johnson B, Masson K, Nielsen U, Schoeberl B, MacBeath G. 438 MM-131: A bispecific antibody that inhibits c-Met signaling through avid binding to the EpCAM tumor antigen European Journal of Cancer. 50: 144. DOI: 10.1016/S0959-8049(14)70564-7  0.147
2021 Oliveira G, Stromhaug K, Klaeger S, Kula T, Frederick DT, Le PM, Forman J, Huang T, Li S, Zhang W, Xu Q, Cieri N, Clauser KR, Shukla SA, Neuberg D, ... ... MacBeath G, et al. Phenotype, specificity and avidity of antitumour CD8 T cells in melanoma. Nature. PMID 34290406 DOI: 10.1038/s41586-021-03704-y  0.135
2012 Curley M, Kalra A, Fulgham A, Xiao D, Allen J, Wainszelbaum M, Garcia G, Kubasek W, MacBeath G. 141 MM-121, an Anti-ErbB3 Antibody, Inhibits PI3K/AKT Signaling and Viability in Platinum-resistant Ovarian Cells and in Primary Ascites Derived From Chemo-resistant Ovarian Cancer Patients European Journal of Cancer. 48: 43-44. DOI: 10.1016/S0959-8049(12)71939-1  0.122
2012 Curley M, Kalra A, Fulgham A, Xiao D, Allen J, Wainszelbaum M, Garcia G, Kubasek W, MacBeath G. 141 MM-121, an Anti-ErbB3 Antibody, Inhibits PI3K/AKT Signaling and Viability in Platinum-resistant Ovarian Cells and in Primary Ascites Derived From Chemo-resistant Ovarian Cancer Patients European Journal of Cancer. 48: 43-44. DOI: 10.1016/S0959-8049(12)71939-1  0.122
2012 Curley M, Kalra A, Fulgham A, Xiao D, Allen J, Wainszelbaum M, Garcia G, Kubasek W, MacBeath G. 141 MM-121, an Anti-ErbB3 Antibody, Inhibits PI3K/AKT Signaling and Viability in Platinum-resistant Ovarian Cells and in Primary Ascites Derived From Chemo-resistant Ovarian Cancer Patients European Journal of Cancer. 48: 43-44. DOI: 10.1016/S0959-8049(12)71939-1  0.122
2012 Curley M, Kalra A, Fulgham A, Xiao D, Allen J, Wainszelbaum M, Garcia G, Kubasek W, MacBeath G. 141 MM-121, an Anti-ErbB3 Antibody, Inhibits PI3K/AKT Signaling and Viability in Platinum-resistant Ovarian Cells and in Primary Ascites Derived From Chemo-resistant Ovarian Cancer Patients European Journal of Cancer. 48: 43-44. DOI: 10.1016/S0959-8049(12)71939-1  0.122
2012 Curley M, Kalra A, Fulgham A, Xiao D, Allen J, Wainszelbaum M, Garcia G, Kubasek W, MacBeath G. 141 MM-121, an Anti-ErbB3 Antibody, Inhibits PI3K/AKT Signaling and Viability in Platinum-resistant Ovarian Cells and in Primary Ascites Derived From Chemo-resistant Ovarian Cancer Patients European Journal of Cancer. 48: 43-44. DOI: 10.1016/S0959-8049(12)71939-1  0.122
2012 Curley M, Kalra A, Fulgham A, Xiao D, Allen J, Wainszelbaum M, Garcia G, Kubasek W, MacBeath G. 141 MM-121, an Anti-ErbB3 Antibody, Inhibits PI3K/AKT Signaling and Viability in Platinum-resistant Ovarian Cells and in Primary Ascites Derived From Chemo-resistant Ovarian Cancer Patients European Journal of Cancer. 48: 43-44. DOI: 10.1016/S0959-8049(12)71939-1  0.122
2012 Curley M, Kalra A, Fulgham A, Xiao D, Allen J, Wainszelbaum M, Garcia G, Kubasek W, MacBeath G. 141 MM-121, an Anti-ErbB3 Antibody, Inhibits PI3K/AKT Signaling and Viability in Platinum-resistant Ovarian Cells and in Primary Ascites Derived From Chemo-resistant Ovarian Cancer Patients European Journal of Cancer. 48: 43-44. DOI: 10.1016/S0959-8049(12)71939-1  0.122
2012 Curley M, Kalra A, Fulgham A, Xiao D, Allen J, Wainszelbaum M, Garcia G, Kubasek W, MacBeath G. 141 MM-121, an Anti-ErbB3 Antibody, Inhibits PI3K/AKT Signaling and Viability in Platinum-resistant Ovarian Cells and in Primary Ascites Derived From Chemo-resistant Ovarian Cancer Patients European Journal of Cancer. 48: 43-44. DOI: 10.1016/S0959-8049(12)71939-1  0.122
2012 Curley M, Kalra A, Fulgham A, Xiao D, Allen J, Wainszelbaum M, Garcia G, Kubasek W, MacBeath G. 141 MM-121, an Anti-ErbB3 Antibody, Inhibits PI3K/AKT Signaling and Viability in Platinum-resistant Ovarian Cells and in Primary Ascites Derived From Chemo-resistant Ovarian Cancer Patients European Journal of Cancer. 48: 43-44. DOI: 10.1016/S0959-8049(12)71939-1  0.122
2012 Curley M, Kalra A, Fulgham A, Xiao D, Allen J, Wainszelbaum M, Garcia G, Kubasek W, MacBeath G. 141 MM-121, an Anti-ErbB3 Antibody, Inhibits PI3K/AKT Signaling and Viability in Platinum-resistant Ovarian Cells and in Primary Ascites Derived From Chemo-resistant Ovarian Cancer Patients European Journal of Cancer. 48: 43-44. DOI: 10.1016/S0959-8049(12)71939-1  0.122
2012 Curley M, Kalra A, Fulgham A, Xiao D, Allen J, Wainszelbaum M, Garcia G, Kubasek W, MacBeath G. 141 MM-121, an Anti-ErbB3 Antibody, Inhibits PI3K/AKT Signaling and Viability in Platinum-resistant Ovarian Cells and in Primary Ascites Derived From Chemo-resistant Ovarian Cancer Patients European Journal of Cancer. 48: 43-44. DOI: 10.1016/S0959-8049(12)71939-1  0.122
2012 Curley M, Kalra A, Fulgham A, Xiao D, Allen J, Wainszelbaum M, Garcia G, Kubasek W, MacBeath G. 141 MM-121, an Anti-ErbB3 Antibody, Inhibits PI3K/AKT Signaling and Viability in Platinum-resistant Ovarian Cells and in Primary Ascites Derived From Chemo-resistant Ovarian Cancer Patients European Journal of Cancer. 48: 43-44. DOI: 10.1016/S0959-8049(12)71939-1  0.122
2012 Curley M, Kalra A, Fulgham A, Xiao D, Allen J, Wainszelbaum M, Garcia G, Kubasek W, MacBeath G. 141 MM-121, an Anti-ErbB3 Antibody, Inhibits PI3K/AKT Signaling and Viability in Platinum-resistant Ovarian Cells and in Primary Ascites Derived From Chemo-resistant Ovarian Cancer Patients European Journal of Cancer. 48: 43-44. DOI: 10.1016/S0959-8049(12)71939-1  0.122
2012 Curley M, Kalra A, Fulgham A, Xiao D, Allen J, Wainszelbaum M, Garcia G, Kubasek W, MacBeath G. 141 MM-121, an Anti-ErbB3 Antibody, Inhibits PI3K/AKT Signaling and Viability in Platinum-resistant Ovarian Cells and in Primary Ascites Derived From Chemo-resistant Ovarian Cancer Patients European Journal of Cancer. 48: 43-44. DOI: 10.1016/S0959-8049(12)71939-1  0.122
2012 Curley M, Kalra A, Fulgham A, Xiao D, Allen J, Wainszelbaum M, Garcia G, Kubasek W, MacBeath G. 141 MM-121, an Anti-ErbB3 Antibody, Inhibits PI3K/AKT Signaling and Viability in Platinum-resistant Ovarian Cells and in Primary Ascites Derived From Chemo-resistant Ovarian Cancer Patients European Journal of Cancer. 48: 43-44. DOI: 10.1016/S0959-8049(12)71939-1  0.122
2012 Curley M, Kalra A, Fulgham A, Xiao D, Allen J, Wainszelbaum M, Garcia G, Kubasek W, MacBeath G. 141 MM-121, an Anti-ErbB3 Antibody, Inhibits PI3K/AKT Signaling and Viability in Platinum-resistant Ovarian Cells and in Primary Ascites Derived From Chemo-resistant Ovarian Cancer Patients European Journal of Cancer. 48: 43-44. DOI: 10.1016/S0959-8049(12)71939-1  0.122
2012 Luckert K, Gujral TS, Chan M, Sevecka M, Joos TO, Sorger PK, MacBeath G, Pötz O. A correction to the protocol titled: "A dual array-based approach to assess the abundance and posttranslational modification state of signaling proteins" by K. Luckert, T. S. Gujral, M. Chan, T. O. Joos, P. K. Sorger, G. MacBeath, O. Pötz Science Signaling. 5. DOI: 10.1126/scisignal.5238er5  0.112
2023 Meyer M, Mahr A, Brewer J, Daniel V, Dell'Aringa J, Goldstone T, Hersey S, Johnston I, Larson P, Loveridge M, MacBeath G, Moyer M, Nagorsen D, Papa S, Peiser L, et al. A call to adapt the regulation of HLA testing for T cell receptor-based therapeutics. Nature Reviews. Drug Discovery. PMID 38030734 DOI: 10.1038/d41573-023-00189-4  0.111
2014 Sequist LV, Lopez-Chavez A, Doebele RC, Gray JE, Harb WA, Modiano MR, Jackman DM, Baggstrom MQ, Atmaca A, Felip E, Provencio M, Cobo M, Kripas CJ, MacBeath G, Czibere AG, et al. A randomized phase 2 trial of MM-121, a fully human monoclonal antibody targeting ErbB3, in combination with erlotinib in EGFR wild-type NSCLC patients. Journal of Clinical Oncology. 32: 8051-8051. DOI: 10.1200/jco.2014.32.15_suppl.8051  0.103
2014 Sequist LV, Lopez-Chavez A, Doebele RC, Gray JE, Harb WA, Modiano MR, Jackman DM, Baggstrom MQ, Atmaca A, Felip E, Provencio M, Cobo M, Kripas CJ, MacBeath G, Czibere AG, et al. A randomized phase 2 trial of MM-121, a fully human monoclonal antibody targeting ErbB3, in combination with erlotinib in EGFR wild-type NSCLC patients. Journal of Clinical Oncology. 32: 8051-8051. DOI: 10.1200/jco.2014.32.15_suppl.8051  0.103
2014 Sequist LV, Lopez-Chavez A, Doebele RC, Gray JE, Harb WA, Modiano MR, Jackman DM, Baggstrom MQ, Atmaca A, Felip E, Provencio M, Cobo M, Kripas CJ, MacBeath G, Czibere AG, et al. A randomized phase 2 trial of MM-121, a fully human monoclonal antibody targeting ErbB3, in combination with erlotinib in EGFR wild-type NSCLC patients. Journal of Clinical Oncology. 32: 8051-8051. DOI: 10.1200/jco.2014.32.15_suppl.8051  0.103
2014 Sequist LV, Lopez-Chavez A, Doebele RC, Gray JE, Harb WA, Modiano MR, Jackman DM, Baggstrom MQ, Atmaca A, Felip E, Provencio M, Cobo M, Kripas CJ, MacBeath G, Czibere AG, et al. A randomized phase 2 trial of MM-121, a fully human monoclonal antibody targeting ErbB3, in combination with erlotinib in EGFR wild-type NSCLC patients. Journal of Clinical Oncology. 32: 8051-8051. DOI: 10.1200/jco.2014.32.15_suppl.8051  0.103
2014 Sequist LV, Lopez-Chavez A, Doebele RC, Gray JE, Harb WA, Modiano MR, Jackman DM, Baggstrom MQ, Atmaca A, Felip E, Provencio M, Cobo M, Kripas CJ, MacBeath G, Czibere AG, et al. A randomized phase 2 trial of MM-121, a fully human monoclonal antibody targeting ErbB3, in combination with erlotinib in EGFR wild-type NSCLC patients. Journal of Clinical Oncology. 32: 8051-8051. DOI: 10.1200/jco.2014.32.15_suppl.8051  0.103
2014 Sequist LV, Lopez-Chavez A, Doebele RC, Gray JE, Harb WA, Modiano MR, Jackman DM, Baggstrom MQ, Atmaca A, Felip E, Provencio M, Cobo M, Kripas CJ, MacBeath G, Czibere AG, et al. A randomized phase 2 trial of MM-121, a fully human monoclonal antibody targeting ErbB3, in combination with erlotinib in EGFR wild-type NSCLC patients. Journal of Clinical Oncology. 32: 8051-8051. DOI: 10.1200/jco.2014.32.15_suppl.8051  0.103
2014 Sequist LV, Lopez-Chavez A, Doebele RC, Gray JE, Harb WA, Modiano MR, Jackman DM, Baggstrom MQ, Atmaca A, Felip E, Provencio M, Cobo M, Kripas CJ, MacBeath G, Czibere AG, et al. A randomized phase 2 trial of MM-121, a fully human monoclonal antibody targeting ErbB3, in combination with erlotinib in EGFR wild-type NSCLC patients. Journal of Clinical Oncology. 32: 8051-8051. DOI: 10.1200/jco.2014.32.15_suppl.8051  0.103
2014 Sequist LV, Lopez-Chavez A, Doebele RC, Gray JE, Harb WA, Modiano MR, Jackman DM, Baggstrom MQ, Atmaca A, Felip E, Provencio M, Cobo M, Kripas CJ, MacBeath G, Czibere AG, et al. A randomized phase 2 trial of MM-121, a fully human monoclonal antibody targeting ErbB3, in combination with erlotinib in EGFR wild-type NSCLC patients. Journal of Clinical Oncology. 32: 8051-8051. DOI: 10.1200/jco.2014.32.15_suppl.8051  0.103
2014 Sequist LV, Lopez-Chavez A, Doebele RC, Gray JE, Harb WA, Modiano MR, Jackman DM, Baggstrom MQ, Atmaca A, Felip E, Provencio M, Cobo M, Kripas CJ, MacBeath G, Czibere AG, et al. A randomized phase 2 trial of MM-121, a fully human monoclonal antibody targeting ErbB3, in combination with erlotinib in EGFR wild-type NSCLC patients. Journal of Clinical Oncology. 32: 8051-8051. DOI: 10.1200/jco.2014.32.15_suppl.8051  0.103
2014 Sequist LV, Lopez-Chavez A, Doebele RC, Gray JE, Harb WA, Modiano MR, Jackman DM, Baggstrom MQ, Atmaca A, Felip E, Provencio M, Cobo M, Kripas CJ, MacBeath G, Czibere AG, et al. A randomized phase 2 trial of MM-121, a fully human monoclonal antibody targeting ErbB3, in combination with erlotinib in EGFR wild-type NSCLC patients. Journal of Clinical Oncology. 32: 8051-8051. DOI: 10.1200/jco.2014.32.15_suppl.8051  0.103
2014 Sequist LV, Lopez-Chavez A, Doebele RC, Gray JE, Harb WA, Modiano MR, Jackman DM, Baggstrom MQ, Atmaca A, Felip E, Provencio M, Cobo M, Kripas CJ, MacBeath G, Czibere AG, et al. A randomized phase 2 trial of MM-121, a fully human monoclonal antibody targeting ErbB3, in combination with erlotinib in EGFR wild-type NSCLC patients. Journal of Clinical Oncology. 32: 8051-8051. DOI: 10.1200/jco.2014.32.15_suppl.8051  0.103
2014 Sequist LV, Lopez-Chavez A, Doebele RC, Gray JE, Harb WA, Modiano MR, Jackman DM, Baggstrom MQ, Atmaca A, Felip E, Provencio M, Cobo M, Kripas CJ, MacBeath G, Czibere AG, et al. A randomized phase 2 trial of MM-121, a fully human monoclonal antibody targeting ErbB3, in combination with erlotinib in EGFR wild-type NSCLC patients. Journal of Clinical Oncology. 32: 8051-8051. DOI: 10.1200/jco.2014.32.15_suppl.8051  0.103
2014 Sequist LV, Lopez-Chavez A, Doebele RC, Gray JE, Harb WA, Modiano MR, Jackman DM, Baggstrom MQ, Atmaca A, Felip E, Provencio M, Cobo M, Kripas CJ, MacBeath G, Czibere AG, et al. A randomized phase 2 trial of MM-121, a fully human monoclonal antibody targeting ErbB3, in combination with erlotinib in EGFR wild-type NSCLC patients. Journal of Clinical Oncology. 32: 8051-8051. DOI: 10.1200/jco.2014.32.15_suppl.8051  0.103
2014 Sequist LV, Lopez-Chavez A, Doebele RC, Gray JE, Harb WA, Modiano MR, Jackman DM, Baggstrom MQ, Atmaca A, Felip E, Provencio M, Cobo M, Kripas CJ, MacBeath G, Czibere AG, et al. A randomized phase 2 trial of MM-121, a fully human monoclonal antibody targeting ErbB3, in combination with erlotinib in EGFR wild-type NSCLC patients. Journal of Clinical Oncology. 32: 8051-8051. DOI: 10.1200/jco.2014.32.15_suppl.8051  0.103
2014 Sequist LV, Lopez-Chavez A, Doebele RC, Gray JE, Harb WA, Modiano MR, Jackman DM, Baggstrom MQ, Atmaca A, Felip E, Provencio M, Cobo M, Kripas CJ, MacBeath G, Czibere AG, et al. A randomized phase 2 trial of MM-121, a fully human monoclonal antibody targeting ErbB3, in combination with erlotinib in EGFR wild-type NSCLC patients. Journal of Clinical Oncology. 32: 8051-8051. DOI: 10.1200/jco.2014.32.15_suppl.8051  0.103
2014 Liu J, Ray-Coquard IL, Selle F, Poveda A, Cibula D, Hirte HW, Raspagliesi F, Gladieff L, Harter P, Schiavetto I, Tabah-Fisch IM, MacBeath G, Czibere AG, Naumann RW, Coleman RL, et al. A phase II randomized open-label study of MM-121, a fully human monoclonal antibody targeting ErbB3, in combination with weekly paclitaxel versus weekly paclitaxel in patients with platinum-resistant/refractory ovarian cancers. Journal of Clinical Oncology. 32: 5519-5519. DOI: 10.1200/jco.2014.32.15_suppl.5519  0.101
2014 Liu J, Ray-Coquard IL, Selle F, Poveda A, Cibula D, Hirte HW, Raspagliesi F, Gladieff L, Harter P, Schiavetto I, Tabah-Fisch IM, MacBeath G, Czibere AG, Naumann RW, Coleman RL, et al. A phase II randomized open-label study of MM-121, a fully human monoclonal antibody targeting ErbB3, in combination with weekly paclitaxel versus weekly paclitaxel in patients with platinum-resistant/refractory ovarian cancers. Journal of Clinical Oncology. 32: 5519-5519. DOI: 10.1200/jco.2014.32.15_suppl.5519  0.101
2014 Liu J, Ray-Coquard IL, Selle F, Poveda A, Cibula D, Hirte HW, Raspagliesi F, Gladieff L, Harter P, Schiavetto I, Tabah-Fisch IM, MacBeath G, Czibere AG, Naumann RW, Coleman RL, et al. A phase II randomized open-label study of MM-121, a fully human monoclonal antibody targeting ErbB3, in combination with weekly paclitaxel versus weekly paclitaxel in patients with platinum-resistant/refractory ovarian cancers. Journal of Clinical Oncology. 32: 5519-5519. DOI: 10.1200/jco.2014.32.15_suppl.5519  0.101
2014 Liu J, Ray-Coquard IL, Selle F, Poveda A, Cibula D, Hirte HW, Raspagliesi F, Gladieff L, Harter P, Schiavetto I, Tabah-Fisch IM, MacBeath G, Czibere AG, Naumann RW, Coleman RL, et al. A phase II randomized open-label study of MM-121, a fully human monoclonal antibody targeting ErbB3, in combination with weekly paclitaxel versus weekly paclitaxel in patients with platinum-resistant/refractory ovarian cancers. Journal of Clinical Oncology. 32: 5519-5519. DOI: 10.1200/jco.2014.32.15_suppl.5519  0.101
2014 Liu J, Ray-Coquard IL, Selle F, Poveda A, Cibula D, Hirte HW, Raspagliesi F, Gladieff L, Harter P, Schiavetto I, Tabah-Fisch IM, MacBeath G, Czibere AG, Naumann RW, Coleman RL, et al. A phase II randomized open-label study of MM-121, a fully human monoclonal antibody targeting ErbB3, in combination with weekly paclitaxel versus weekly paclitaxel in patients with platinum-resistant/refractory ovarian cancers. Journal of Clinical Oncology. 32: 5519-5519. DOI: 10.1200/jco.2014.32.15_suppl.5519  0.101
2014 Liu J, Ray-Coquard IL, Selle F, Poveda A, Cibula D, Hirte HW, Raspagliesi F, Gladieff L, Harter P, Schiavetto I, Tabah-Fisch IM, MacBeath G, Czibere AG, Naumann RW, Coleman RL, et al. A phase II randomized open-label study of MM-121, a fully human monoclonal antibody targeting ErbB3, in combination with weekly paclitaxel versus weekly paclitaxel in patients with platinum-resistant/refractory ovarian cancers. Journal of Clinical Oncology. 32: 5519-5519. DOI: 10.1200/jco.2014.32.15_suppl.5519  0.101
2014 Liu J, Ray-Coquard IL, Selle F, Poveda A, Cibula D, Hirte HW, Raspagliesi F, Gladieff L, Harter P, Schiavetto I, Tabah-Fisch IM, MacBeath G, Czibere AG, Naumann RW, Coleman RL, et al. A phase II randomized open-label study of MM-121, a fully human monoclonal antibody targeting ErbB3, in combination with weekly paclitaxel versus weekly paclitaxel in patients with platinum-resistant/refractory ovarian cancers. Journal of Clinical Oncology. 32: 5519-5519. DOI: 10.1200/jco.2014.32.15_suppl.5519  0.101
2014 Liu J, Ray-Coquard IL, Selle F, Poveda A, Cibula D, Hirte HW, Raspagliesi F, Gladieff L, Harter P, Schiavetto I, Tabah-Fisch IM, MacBeath G, Czibere AG, Naumann RW, Coleman RL, et al. A phase II randomized open-label study of MM-121, a fully human monoclonal antibody targeting ErbB3, in combination with weekly paclitaxel versus weekly paclitaxel in patients with platinum-resistant/refractory ovarian cancers. Journal of Clinical Oncology. 32: 5519-5519. DOI: 10.1200/jco.2014.32.15_suppl.5519  0.101
2014 Liu J, Ray-Coquard IL, Selle F, Poveda A, Cibula D, Hirte HW, Raspagliesi F, Gladieff L, Harter P, Schiavetto I, Tabah-Fisch IM, MacBeath G, Czibere AG, Naumann RW, Coleman RL, et al. A phase II randomized open-label study of MM-121, a fully human monoclonal antibody targeting ErbB3, in combination with weekly paclitaxel versus weekly paclitaxel in patients with platinum-resistant/refractory ovarian cancers. Journal of Clinical Oncology. 32: 5519-5519. DOI: 10.1200/jco.2014.32.15_suppl.5519  0.101
2014 Liu J, Ray-Coquard IL, Selle F, Poveda A, Cibula D, Hirte HW, Raspagliesi F, Gladieff L, Harter P, Schiavetto I, Tabah-Fisch IM, MacBeath G, Czibere AG, Naumann RW, Coleman RL, et al. A phase II randomized open-label study of MM-121, a fully human monoclonal antibody targeting ErbB3, in combination with weekly paclitaxel versus weekly paclitaxel in patients with platinum-resistant/refractory ovarian cancers. Journal of Clinical Oncology. 32: 5519-5519. DOI: 10.1200/jco.2014.32.15_suppl.5519  0.101
2014 Liu J, Ray-Coquard IL, Selle F, Poveda A, Cibula D, Hirte HW, Raspagliesi F, Gladieff L, Harter P, Schiavetto I, Tabah-Fisch IM, MacBeath G, Czibere AG, Naumann RW, Coleman RL, et al. A phase II randomized open-label study of MM-121, a fully human monoclonal antibody targeting ErbB3, in combination with weekly paclitaxel versus weekly paclitaxel in patients with platinum-resistant/refractory ovarian cancers. Journal of Clinical Oncology. 32: 5519-5519. DOI: 10.1200/jco.2014.32.15_suppl.5519  0.101
2014 Liu J, Ray-Coquard IL, Selle F, Poveda A, Cibula D, Hirte HW, Raspagliesi F, Gladieff L, Harter P, Schiavetto I, Tabah-Fisch IM, MacBeath G, Czibere AG, Naumann RW, Coleman RL, et al. A phase II randomized open-label study of MM-121, a fully human monoclonal antibody targeting ErbB3, in combination with weekly paclitaxel versus weekly paclitaxel in patients with platinum-resistant/refractory ovarian cancers. Journal of Clinical Oncology. 32: 5519-5519. DOI: 10.1200/jco.2014.32.15_suppl.5519  0.101
2014 Liu J, Ray-Coquard IL, Selle F, Poveda A, Cibula D, Hirte HW, Raspagliesi F, Gladieff L, Harter P, Schiavetto I, Tabah-Fisch IM, MacBeath G, Czibere AG, Naumann RW, Coleman RL, et al. A phase II randomized open-label study of MM-121, a fully human monoclonal antibody targeting ErbB3, in combination with weekly paclitaxel versus weekly paclitaxel in patients with platinum-resistant/refractory ovarian cancers. Journal of Clinical Oncology. 32: 5519-5519. DOI: 10.1200/jco.2014.32.15_suppl.5519  0.101
2014 Liu J, Ray-Coquard IL, Selle F, Poveda A, Cibula D, Hirte HW, Raspagliesi F, Gladieff L, Harter P, Schiavetto I, Tabah-Fisch IM, MacBeath G, Czibere AG, Naumann RW, Coleman RL, et al. A phase II randomized open-label study of MM-121, a fully human monoclonal antibody targeting ErbB3, in combination with weekly paclitaxel versus weekly paclitaxel in patients with platinum-resistant/refractory ovarian cancers. Journal of Clinical Oncology. 32: 5519-5519. DOI: 10.1200/jco.2014.32.15_suppl.5519  0.101
2014 Liu J, Ray-Coquard IL, Selle F, Poveda A, Cibula D, Hirte HW, Raspagliesi F, Gladieff L, Harter P, Schiavetto I, Tabah-Fisch IM, MacBeath G, Czibere AG, Naumann RW, Coleman RL, et al. A phase II randomized open-label study of MM-121, a fully human monoclonal antibody targeting ErbB3, in combination with weekly paclitaxel versus weekly paclitaxel in patients with platinum-resistant/refractory ovarian cancers. Journal of Clinical Oncology. 32: 5519-5519. DOI: 10.1200/jco.2014.32.15_suppl.5519  0.101
2022 Luoma AM, Suo S, Wang Y, Gunasti L, Porter CBM, Nabilsi N, Tadros J, Ferretti AP, Liao S, Gurer C, Chen YH, Criscitiello S, Ricker CA, Dionne D, Rozenblatt-Rosen O, ... ... MacBeath G, et al. Tissue-resident memory and circulating T cells are early responders to pre-surgical cancer immunotherapy. Cell. PMID 35803260 DOI: 10.1016/j.cell.2022.06.018  0.097
2014 Macbeath G, Adiwijaya B, Liu J, Sequist L, Pujade-Lauraine E, Higgins M, Tabah-Fisch I, Pearlberg J, Moyo V, Kubasek W, Nering R, Czibere A. A Meta-Analysis of Biomarkers in Three Randomized, Phase 2 Studies of Mm-121, a Ligand-Blocking Anti-Erbb3 Antibody, in Patients with Ovarian, Lung, and Breast Cancers Annals of Oncology. 25: iv82. DOI: 10.1093/annonc/mdu326.79  0.096
2014 Macbeath G, Adiwijaya B, Liu J, Sequist L, Pujade-Lauraine E, Higgins M, Tabah-Fisch I, Pearlberg J, Moyo V, Kubasek W, Nering R, Czibere A. A Meta-Analysis of Biomarkers in Three Randomized, Phase 2 Studies of Mm-121, a Ligand-Blocking Anti-Erbb3 Antibody, in Patients with Ovarian, Lung, and Breast Cancers Annals of Oncology. 25: iv82. DOI: 10.1093/annonc/mdu326.79  0.096
2014 Macbeath G, Adiwijaya B, Liu J, Sequist L, Pujade-Lauraine E, Higgins M, Tabah-Fisch I, Pearlberg J, Moyo V, Kubasek W, Nering R, Czibere A. A Meta-Analysis of Biomarkers in Three Randomized, Phase 2 Studies of Mm-121, a Ligand-Blocking Anti-Erbb3 Antibody, in Patients with Ovarian, Lung, and Breast Cancers Annals of Oncology. 25: iv82. DOI: 10.1093/annonc/mdu326.79  0.096
2014 Macbeath G, Adiwijaya B, Liu J, Sequist L, Pujade-Lauraine E, Higgins M, Tabah-Fisch I, Pearlberg J, Moyo V, Kubasek W, Nering R, Czibere A. A Meta-Analysis of Biomarkers in Three Randomized, Phase 2 Studies of Mm-121, a Ligand-Blocking Anti-Erbb3 Antibody, in Patients with Ovarian, Lung, and Breast Cancers Annals of Oncology. 25: iv82. DOI: 10.1093/annonc/mdu326.79  0.096
2014 Macbeath G, Adiwijaya B, Liu J, Sequist L, Pujade-Lauraine E, Higgins M, Tabah-Fisch I, Pearlberg J, Moyo V, Kubasek W, Nering R, Czibere A. A Meta-Analysis of Biomarkers in Three Randomized, Phase 2 Studies of Mm-121, a Ligand-Blocking Anti-Erbb3 Antibody, in Patients with Ovarian, Lung, and Breast Cancers Annals of Oncology. 25: iv82. DOI: 10.1093/annonc/mdu326.79  0.096
2014 Macbeath G, Adiwijaya B, Liu J, Sequist L, Pujade-Lauraine E, Higgins M, Tabah-Fisch I, Pearlberg J, Moyo V, Kubasek W, Nering R, Czibere A. A Meta-Analysis of Biomarkers in Three Randomized, Phase 2 Studies of Mm-121, a Ligand-Blocking Anti-Erbb3 Antibody, in Patients with Ovarian, Lung, and Breast Cancers Annals of Oncology. 25: iv82. DOI: 10.1093/annonc/mdu326.79  0.096
2014 Macbeath G, Adiwijaya B, Liu J, Sequist L, Pujade-Lauraine E, Higgins M, Tabah-Fisch I, Pearlberg J, Moyo V, Kubasek W, Nering R, Czibere A. A Meta-Analysis of Biomarkers in Three Randomized, Phase 2 Studies of Mm-121, a Ligand-Blocking Anti-Erbb3 Antibody, in Patients with Ovarian, Lung, and Breast Cancers Annals of Oncology. 25: iv82. DOI: 10.1093/annonc/mdu326.79  0.096
2014 Macbeath G, Adiwijaya B, Liu J, Sequist L, Pujade-Lauraine E, Higgins M, Tabah-Fisch I, Pearlberg J, Moyo V, Kubasek W, Nering R, Czibere A. A Meta-Analysis of Biomarkers in Three Randomized, Phase 2 Studies of Mm-121, a Ligand-Blocking Anti-Erbb3 Antibody, in Patients with Ovarian, Lung, and Breast Cancers Annals of Oncology. 25: iv82. DOI: 10.1093/annonc/mdu326.79  0.096
2014 Macbeath G, Adiwijaya B, Liu J, Sequist L, Pujade-Lauraine E, Higgins M, Tabah-Fisch I, Pearlberg J, Moyo V, Kubasek W, Nering R, Czibere A. A Meta-Analysis of Biomarkers in Three Randomized, Phase 2 Studies of Mm-121, a Ligand-Blocking Anti-Erbb3 Antibody, in Patients with Ovarian, Lung, and Breast Cancers Annals of Oncology. 25: iv82. DOI: 10.1093/annonc/mdu326.79  0.096
2014 Macbeath G, Adiwijaya B, Liu J, Sequist L, Pujade-Lauraine E, Higgins M, Tabah-Fisch I, Pearlberg J, Moyo V, Kubasek W, Nering R, Czibere A. A Meta-Analysis of Biomarkers in Three Randomized, Phase 2 Studies of Mm-121, a Ligand-Blocking Anti-Erbb3 Antibody, in Patients with Ovarian, Lung, and Breast Cancers Annals of Oncology. 25: iv82. DOI: 10.1093/annonc/mdu326.79  0.096
2014 Macbeath G, Adiwijaya B, Liu J, Sequist L, Pujade-Lauraine E, Higgins M, Tabah-Fisch I, Pearlberg J, Moyo V, Kubasek W, Nering R, Czibere A. A Meta-Analysis of Biomarkers in Three Randomized, Phase 2 Studies of Mm-121, a Ligand-Blocking Anti-Erbb3 Antibody, in Patients with Ovarian, Lung, and Breast Cancers Annals of Oncology. 25: iv82. DOI: 10.1093/annonc/mdu326.79  0.096
2014 Macbeath G, Adiwijaya B, Liu J, Sequist L, Pujade-Lauraine E, Higgins M, Tabah-Fisch I, Pearlberg J, Moyo V, Kubasek W, Nering R, Czibere A. A Meta-Analysis of Biomarkers in Three Randomized, Phase 2 Studies of Mm-121, a Ligand-Blocking Anti-Erbb3 Antibody, in Patients with Ovarian, Lung, and Breast Cancers Annals of Oncology. 25: iv82. DOI: 10.1093/annonc/mdu326.79  0.096
2014 Macbeath G, Adiwijaya B, Liu J, Sequist L, Pujade-Lauraine E, Higgins M, Tabah-Fisch I, Pearlberg J, Moyo V, Kubasek W, Nering R, Czibere A. A Meta-Analysis of Biomarkers in Three Randomized, Phase 2 Studies of Mm-121, a Ligand-Blocking Anti-Erbb3 Antibody, in Patients with Ovarian, Lung, and Breast Cancers Annals of Oncology. 25: iv82. DOI: 10.1093/annonc/mdu326.79  0.096
2014 Macbeath G, Adiwijaya B, Liu J, Sequist L, Pujade-Lauraine E, Higgins M, Tabah-Fisch I, Pearlberg J, Moyo V, Kubasek W, Nering R, Czibere A. A Meta-Analysis of Biomarkers in Three Randomized, Phase 2 Studies of Mm-121, a Ligand-Blocking Anti-Erbb3 Antibody, in Patients with Ovarian, Lung, and Breast Cancers Annals of Oncology. 25: iv82. DOI: 10.1093/annonc/mdu326.79  0.096
2014 Macbeath G, Adiwijaya B, Liu J, Sequist L, Pujade-Lauraine E, Higgins M, Tabah-Fisch I, Pearlberg J, Moyo V, Kubasek W, Nering R, Czibere A. A Meta-Analysis of Biomarkers in Three Randomized, Phase 2 Studies of Mm-121, a Ligand-Blocking Anti-Erbb3 Antibody, in Patients with Ovarian, Lung, and Breast Cancers Annals of Oncology. 25: iv82. DOI: 10.1093/annonc/mdu326.79  0.096
2014 Saba NF, Qian G, Ning J, Kim S, Chen Z, Garcia G, MacBeath G, Shin DM, Khuri FR, Chen ZG. Expressions of EGFR, HER2, and HER3 and their correlations with clinical characteristics in oropharyngeal squamous cell carcinoma (OPSCC). Journal of Clinical Oncology. 32: 6068-6068. DOI: 10.1200/jco.2014.32.15_suppl.6068  0.095
2014 Saba NF, Qian G, Ning J, Kim S, Chen Z, Garcia G, MacBeath G, Shin DM, Khuri FR, Chen ZG. Expressions of EGFR, HER2, and HER3 and their correlations with clinical characteristics in oropharyngeal squamous cell carcinoma (OPSCC). Journal of Clinical Oncology. 32: 6068-6068. DOI: 10.1200/jco.2014.32.15_suppl.6068  0.095
2014 Saba NF, Qian G, Ning J, Kim S, Chen Z, Garcia G, MacBeath G, Shin DM, Khuri FR, Chen ZG. Expressions of EGFR, HER2, and HER3 and their correlations with clinical characteristics in oropharyngeal squamous cell carcinoma (OPSCC). Journal of Clinical Oncology. 32: 6068-6068. DOI: 10.1200/jco.2014.32.15_suppl.6068  0.095
2014 Saba NF, Qian G, Ning J, Kim S, Chen Z, Garcia G, MacBeath G, Shin DM, Khuri FR, Chen ZG. Expressions of EGFR, HER2, and HER3 and their correlations with clinical characteristics in oropharyngeal squamous cell carcinoma (OPSCC). Journal of Clinical Oncology. 32: 6068-6068. DOI: 10.1200/jco.2014.32.15_suppl.6068  0.095
2014 Saba NF, Qian G, Ning J, Kim S, Chen Z, Garcia G, MacBeath G, Shin DM, Khuri FR, Chen ZG. Expressions of EGFR, HER2, and HER3 and their correlations with clinical characteristics in oropharyngeal squamous cell carcinoma (OPSCC). Journal of Clinical Oncology. 32: 6068-6068. DOI: 10.1200/jco.2014.32.15_suppl.6068  0.095
2014 Saba NF, Qian G, Ning J, Kim S, Chen Z, Garcia G, MacBeath G, Shin DM, Khuri FR, Chen ZG. Expressions of EGFR, HER2, and HER3 and their correlations with clinical characteristics in oropharyngeal squamous cell carcinoma (OPSCC). Journal of Clinical Oncology. 32: 6068-6068. DOI: 10.1200/jco.2014.32.15_suppl.6068  0.095
2014 Saba NF, Qian G, Ning J, Kim S, Chen Z, Garcia G, MacBeath G, Shin DM, Khuri FR, Chen ZG. Expressions of EGFR, HER2, and HER3 and their correlations with clinical characteristics in oropharyngeal squamous cell carcinoma (OPSCC). Journal of Clinical Oncology. 32: 6068-6068. DOI: 10.1200/jco.2014.32.15_suppl.6068  0.095
2014 Saba NF, Qian G, Ning J, Kim S, Chen Z, Garcia G, MacBeath G, Shin DM, Khuri FR, Chen ZG. Expressions of EGFR, HER2, and HER3 and their correlations with clinical characteristics in oropharyngeal squamous cell carcinoma (OPSCC). Journal of Clinical Oncology. 32: 6068-6068. DOI: 10.1200/jco.2014.32.15_suppl.6068  0.095
2014 Saba NF, Qian G, Ning J, Kim S, Chen Z, Garcia G, MacBeath G, Shin DM, Khuri FR, Chen ZG. Expressions of EGFR, HER2, and HER3 and their correlations with clinical characteristics in oropharyngeal squamous cell carcinoma (OPSCC). Journal of Clinical Oncology. 32: 6068-6068. DOI: 10.1200/jco.2014.32.15_suppl.6068  0.095
2014 Saba NF, Qian G, Ning J, Kim S, Chen Z, Garcia G, MacBeath G, Shin DM, Khuri FR, Chen ZG. Expressions of EGFR, HER2, and HER3 and their correlations with clinical characteristics in oropharyngeal squamous cell carcinoma (OPSCC). Journal of Clinical Oncology. 32: 6068-6068. DOI: 10.1200/jco.2014.32.15_suppl.6068  0.095
2014 Saba NF, Qian G, Ning J, Kim S, Chen Z, Garcia G, MacBeath G, Shin DM, Khuri FR, Chen ZG. Expressions of EGFR, HER2, and HER3 and their correlations with clinical characteristics in oropharyngeal squamous cell carcinoma (OPSCC). Journal of Clinical Oncology. 32: 6068-6068. DOI: 10.1200/jco.2014.32.15_suppl.6068  0.095
2014 Saba NF, Qian G, Ning J, Kim S, Chen Z, Garcia G, MacBeath G, Shin DM, Khuri FR, Chen ZG. Expressions of EGFR, HER2, and HER3 and their correlations with clinical characteristics in oropharyngeal squamous cell carcinoma (OPSCC). Journal of Clinical Oncology. 32: 6068-6068. DOI: 10.1200/jco.2014.32.15_suppl.6068  0.095
2014 Saba NF, Qian G, Ning J, Kim S, Chen Z, Garcia G, MacBeath G, Shin DM, Khuri FR, Chen ZG. Expressions of EGFR, HER2, and HER3 and their correlations with clinical characteristics in oropharyngeal squamous cell carcinoma (OPSCC). Journal of Clinical Oncology. 32: 6068-6068. DOI: 10.1200/jco.2014.32.15_suppl.6068  0.095
2014 Saba NF, Qian G, Ning J, Kim S, Chen Z, Garcia G, MacBeath G, Shin DM, Khuri FR, Chen ZG. Expressions of EGFR, HER2, and HER3 and their correlations with clinical characteristics in oropharyngeal squamous cell carcinoma (OPSCC). Journal of Clinical Oncology. 32: 6068-6068. DOI: 10.1200/jco.2014.32.15_suppl.6068  0.095
2014 Saba NF, Qian G, Ning J, Kim S, Chen Z, Garcia G, MacBeath G, Shin DM, Khuri FR, Chen ZG. Expressions of EGFR, HER2, and HER3 and their correlations with clinical characteristics in oropharyngeal squamous cell carcinoma (OPSCC). Journal of Clinical Oncology. 32: 6068-6068. DOI: 10.1200/jco.2014.32.15_suppl.6068  0.095
2016 Bazdar-Vinovrski B, Wainszelbaum M, MacBeath G. A phase 1 biomarker-directed multi-arm study evaluating the co-administration of MM-151 with MM-121, MM-141, or trametinib in EGFR-driven cancers. Journal of Clinical Oncology. 34: TPS11619-TPS11619. DOI: 10.1200/jco.2016.34.15_suppl.tps11619  0.095
2016 Bazdar-Vinovrski B, Wainszelbaum M, MacBeath G. A phase 1 biomarker-directed multi-arm study evaluating the co-administration of MM-151 with MM-121, MM-141, or trametinib in EGFR-driven cancers. Journal of Clinical Oncology. 34: TPS11619-TPS11619. DOI: 10.1200/jco.2016.34.15_suppl.tps11619  0.095
2016 Bazdar-Vinovrski B, Wainszelbaum M, MacBeath G. A phase 1 biomarker-directed multi-arm study evaluating the co-administration of MM-151 with MM-121, MM-141, or trametinib in EGFR-driven cancers. Journal of Clinical Oncology. 34: TPS11619-TPS11619. DOI: 10.1200/jco.2016.34.15_suppl.tps11619  0.095
2016 Bazdar-Vinovrski B, Wainszelbaum M, MacBeath G. A phase 1 biomarker-directed multi-arm study evaluating the co-administration of MM-151 with MM-121, MM-141, or trametinib in EGFR-driven cancers. Journal of Clinical Oncology. 34: TPS11619-TPS11619. DOI: 10.1200/jco.2016.34.15_suppl.tps11619  0.095
2016 Bazdar-Vinovrski B, Wainszelbaum M, MacBeath G. A phase 1 biomarker-directed multi-arm study evaluating the co-administration of MM-151 with MM-121, MM-141, or trametinib in EGFR-driven cancers. Journal of Clinical Oncology. 34: TPS11619-TPS11619. DOI: 10.1200/jco.2016.34.15_suppl.tps11619  0.095
2016 Bazdar-Vinovrski B, Wainszelbaum M, MacBeath G. A phase 1 biomarker-directed multi-arm study evaluating the co-administration of MM-151 with MM-121, MM-141, or trametinib in EGFR-driven cancers. Journal of Clinical Oncology. 34: TPS11619-TPS11619. DOI: 10.1200/jco.2016.34.15_suppl.tps11619  0.095
2016 Bazdar-Vinovrski B, Wainszelbaum M, MacBeath G. A phase 1 biomarker-directed multi-arm study evaluating the co-administration of MM-151 with MM-121, MM-141, or trametinib in EGFR-driven cancers. Journal of Clinical Oncology. 34: TPS11619-TPS11619. DOI: 10.1200/jco.2016.34.15_suppl.tps11619  0.095
2016 Bazdar-Vinovrski B, Wainszelbaum M, MacBeath G. A phase 1 biomarker-directed multi-arm study evaluating the co-administration of MM-151 with MM-121, MM-141, or trametinib in EGFR-driven cancers. Journal of Clinical Oncology. 34: TPS11619-TPS11619. DOI: 10.1200/jco.2016.34.15_suppl.tps11619  0.095
2016 Bazdar-Vinovrski B, Wainszelbaum M, MacBeath G. A phase 1 biomarker-directed multi-arm study evaluating the co-administration of MM-151 with MM-121, MM-141, or trametinib in EGFR-driven cancers. Journal of Clinical Oncology. 34: TPS11619-TPS11619. DOI: 10.1200/jco.2016.34.15_suppl.tps11619  0.095
2016 Bazdar-Vinovrski B, Wainszelbaum M, MacBeath G. A phase 1 biomarker-directed multi-arm study evaluating the co-administration of MM-151 with MM-121, MM-141, or trametinib in EGFR-driven cancers. Journal of Clinical Oncology. 34: TPS11619-TPS11619. DOI: 10.1200/jco.2016.34.15_suppl.tps11619  0.095
2016 Bazdar-Vinovrski B, Wainszelbaum M, MacBeath G. A phase 1 biomarker-directed multi-arm study evaluating the co-administration of MM-151 with MM-121, MM-141, or trametinib in EGFR-driven cancers. Journal of Clinical Oncology. 34: TPS11619-TPS11619. DOI: 10.1200/jco.2016.34.15_suppl.tps11619  0.095
2016 Bazdar-Vinovrski B, Wainszelbaum M, MacBeath G. A phase 1 biomarker-directed multi-arm study evaluating the co-administration of MM-151 with MM-121, MM-141, or trametinib in EGFR-driven cancers. Journal of Clinical Oncology. 34: TPS11619-TPS11619. DOI: 10.1200/jco.2016.34.15_suppl.tps11619  0.095
2016 Bazdar-Vinovrski B, Wainszelbaum M, MacBeath G. A phase 1 biomarker-directed multi-arm study evaluating the co-administration of MM-151 with MM-121, MM-141, or trametinib in EGFR-driven cancers. Journal of Clinical Oncology. 34: TPS11619-TPS11619. DOI: 10.1200/jco.2016.34.15_suppl.tps11619  0.095
2016 Bazdar-Vinovrski B, Wainszelbaum M, MacBeath G. A phase 1 biomarker-directed multi-arm study evaluating the co-administration of MM-151 with MM-121, MM-141, or trametinib in EGFR-driven cancers. Journal of Clinical Oncology. 34: TPS11619-TPS11619. DOI: 10.1200/jco.2016.34.15_suppl.tps11619  0.095
2016 Bazdar-Vinovrski B, Wainszelbaum M, MacBeath G. A phase 1 biomarker-directed multi-arm study evaluating the co-administration of MM-151 with MM-121, MM-141, or trametinib in EGFR-driven cancers. Journal of Clinical Oncology. 34: TPS11619-TPS11619. DOI: 10.1200/jco.2016.34.15_suppl.tps11619  0.095
2016 Lahdenranta J, Gerami-Moayed N, Burenkova O, Masson K, Raue A, Wainszelbaum M, MacBeath G. The oligoclonal anti-EGFR antibody MM-151 synergizes with trametinib in KRAS wildtype and mutant colorectal cancer models resistant to conventional monoclonal anti-EGFR antibodies European Journal of Cancer. 69: S131. DOI: 10.1016/S0959-8049(16)32989-6  0.081
2016 Lahdenranta J, Gerami-Moayed N, Burenkova O, Masson K, Raue A, Wainszelbaum M, MacBeath G. The oligoclonal anti-EGFR antibody MM-151 synergizes with trametinib in KRAS wildtype and mutant colorectal cancer models resistant to conventional monoclonal anti-EGFR antibodies European Journal of Cancer. 69: S131. DOI: 10.1016/S0959-8049(16)32989-6  0.081
2016 Lahdenranta J, Gerami-Moayed N, Burenkova O, Masson K, Raue A, Wainszelbaum M, MacBeath G. The oligoclonal anti-EGFR antibody MM-151 synergizes with trametinib in KRAS wildtype and mutant colorectal cancer models resistant to conventional monoclonal anti-EGFR antibodies European Journal of Cancer. 69: S131. DOI: 10.1016/S0959-8049(16)32989-6  0.081
2016 Lahdenranta J, Gerami-Moayed N, Burenkova O, Masson K, Raue A, Wainszelbaum M, MacBeath G. The oligoclonal anti-EGFR antibody MM-151 synergizes with trametinib in KRAS wildtype and mutant colorectal cancer models resistant to conventional monoclonal anti-EGFR antibodies European Journal of Cancer. 69: S131. DOI: 10.1016/S0959-8049(16)32989-6  0.081
2016 Lahdenranta J, Gerami-Moayed N, Burenkova O, Masson K, Raue A, Wainszelbaum M, MacBeath G. The oligoclonal anti-EGFR antibody MM-151 synergizes with trametinib in KRAS wildtype and mutant colorectal cancer models resistant to conventional monoclonal anti-EGFR antibodies European Journal of Cancer. 69: S131. DOI: 10.1016/S0959-8049(16)32989-6  0.081
2016 Lahdenranta J, Gerami-Moayed N, Burenkova O, Masson K, Raue A, Wainszelbaum M, MacBeath G. The oligoclonal anti-EGFR antibody MM-151 synergizes with trametinib in KRAS wildtype and mutant colorectal cancer models resistant to conventional monoclonal anti-EGFR antibodies European Journal of Cancer. 69: S131. DOI: 10.1016/S0959-8049(16)32989-6  0.081
2016 Lahdenranta J, Gerami-Moayed N, Burenkova O, Masson K, Raue A, Wainszelbaum M, MacBeath G. The oligoclonal anti-EGFR antibody MM-151 synergizes with trametinib in KRAS wildtype and mutant colorectal cancer models resistant to conventional monoclonal anti-EGFR antibodies European Journal of Cancer. 69: S131. DOI: 10.1016/S0959-8049(16)32989-6  0.081
2016 Lahdenranta J, Gerami-Moayed N, Burenkova O, Masson K, Raue A, Wainszelbaum M, MacBeath G. The oligoclonal anti-EGFR antibody MM-151 synergizes with trametinib in KRAS wildtype and mutant colorectal cancer models resistant to conventional monoclonal anti-EGFR antibodies European Journal of Cancer. 69: S131. DOI: 10.1016/S0959-8049(16)32989-6  0.081
2016 Lahdenranta J, Gerami-Moayed N, Burenkova O, Masson K, Raue A, Wainszelbaum M, MacBeath G. The oligoclonal anti-EGFR antibody MM-151 synergizes with trametinib in KRAS wildtype and mutant colorectal cancer models resistant to conventional monoclonal anti-EGFR antibodies European Journal of Cancer. 69: S131. DOI: 10.1016/S0959-8049(16)32989-6  0.081
2016 Lahdenranta J, Gerami-Moayed N, Burenkova O, Masson K, Raue A, Wainszelbaum M, MacBeath G. The oligoclonal anti-EGFR antibody MM-151 synergizes with trametinib in KRAS wildtype and mutant colorectal cancer models resistant to conventional monoclonal anti-EGFR antibodies European Journal of Cancer. 69: S131. DOI: 10.1016/S0959-8049(16)32989-6  0.081
2014 Higgins MJ, Doyle C, Paepke S, Azaro A, Martin M, Semiglazov V, Smirnova I, Krasnozhon D, Manikhas A, Harb WA, Panasci LC, Pearlberg J, MacBeath G, Nering R, Goss PE, et al. A randomized, double-blind phase II trial of exemestane plus MM-121 (a monoclonal antibody targeting ErbB3) or placebo in postmenopausal women with locally advanced or metastatic ER+/PR+, HER2-negative breast cancer. Journal of Clinical Oncology. 32: 587-587. DOI: 10.1200/jco.2014.32.15_suppl.587  0.08
2014 Higgins MJ, Doyle C, Paepke S, Azaro A, Martin M, Semiglazov V, Smirnova I, Krasnozhon D, Manikhas A, Harb WA, Panasci LC, Pearlberg J, MacBeath G, Nering R, Goss PE, et al. A randomized, double-blind phase II trial of exemestane plus MM-121 (a monoclonal antibody targeting ErbB3) or placebo in postmenopausal women with locally advanced or metastatic ER+/PR+, HER2-negative breast cancer. Journal of Clinical Oncology. 32: 587-587. DOI: 10.1200/jco.2014.32.15_suppl.587  0.08
2014 Higgins MJ, Doyle C, Paepke S, Azaro A, Martin M, Semiglazov V, Smirnova I, Krasnozhon D, Manikhas A, Harb WA, Panasci LC, Pearlberg J, MacBeath G, Nering R, Goss PE, et al. A randomized, double-blind phase II trial of exemestane plus MM-121 (a monoclonal antibody targeting ErbB3) or placebo in postmenopausal women with locally advanced or metastatic ER+/PR+, HER2-negative breast cancer. Journal of Clinical Oncology. 32: 587-587. DOI: 10.1200/jco.2014.32.15_suppl.587  0.08
2014 Higgins MJ, Doyle C, Paepke S, Azaro A, Martin M, Semiglazov V, Smirnova I, Krasnozhon D, Manikhas A, Harb WA, Panasci LC, Pearlberg J, MacBeath G, Nering R, Goss PE, et al. A randomized, double-blind phase II trial of exemestane plus MM-121 (a monoclonal antibody targeting ErbB3) or placebo in postmenopausal women with locally advanced or metastatic ER+/PR+, HER2-negative breast cancer. Journal of Clinical Oncology. 32: 587-587. DOI: 10.1200/jco.2014.32.15_suppl.587  0.08
2014 Higgins MJ, Doyle C, Paepke S, Azaro A, Martin M, Semiglazov V, Smirnova I, Krasnozhon D, Manikhas A, Harb WA, Panasci LC, Pearlberg J, MacBeath G, Nering R, Goss PE, et al. A randomized, double-blind phase II trial of exemestane plus MM-121 (a monoclonal antibody targeting ErbB3) or placebo in postmenopausal women with locally advanced or metastatic ER+/PR+, HER2-negative breast cancer. Journal of Clinical Oncology. 32: 587-587. DOI: 10.1200/jco.2014.32.15_suppl.587  0.08
2014 Higgins MJ, Doyle C, Paepke S, Azaro A, Martin M, Semiglazov V, Smirnova I, Krasnozhon D, Manikhas A, Harb WA, Panasci LC, Pearlberg J, MacBeath G, Nering R, Goss PE, et al. A randomized, double-blind phase II trial of exemestane plus MM-121 (a monoclonal antibody targeting ErbB3) or placebo in postmenopausal women with locally advanced or metastatic ER+/PR+, HER2-negative breast cancer. Journal of Clinical Oncology. 32: 587-587. DOI: 10.1200/jco.2014.32.15_suppl.587  0.08
2014 Higgins MJ, Doyle C, Paepke S, Azaro A, Martin M, Semiglazov V, Smirnova I, Krasnozhon D, Manikhas A, Harb WA, Panasci LC, Pearlberg J, MacBeath G, Nering R, Goss PE, et al. A randomized, double-blind phase II trial of exemestane plus MM-121 (a monoclonal antibody targeting ErbB3) or placebo in postmenopausal women with locally advanced or metastatic ER+/PR+, HER2-negative breast cancer. Journal of Clinical Oncology. 32: 587-587. DOI: 10.1200/jco.2014.32.15_suppl.587  0.08
2014 Higgins MJ, Doyle C, Paepke S, Azaro A, Martin M, Semiglazov V, Smirnova I, Krasnozhon D, Manikhas A, Harb WA, Panasci LC, Pearlberg J, MacBeath G, Nering R, Goss PE, et al. A randomized, double-blind phase II trial of exemestane plus MM-121 (a monoclonal antibody targeting ErbB3) or placebo in postmenopausal women with locally advanced or metastatic ER+/PR+, HER2-negative breast cancer. Journal of Clinical Oncology. 32: 587-587. DOI: 10.1200/jco.2014.32.15_suppl.587  0.08
2014 Higgins MJ, Doyle C, Paepke S, Azaro A, Martin M, Semiglazov V, Smirnova I, Krasnozhon D, Manikhas A, Harb WA, Panasci LC, Pearlberg J, MacBeath G, Nering R, Goss PE, et al. A randomized, double-blind phase II trial of exemestane plus MM-121 (a monoclonal antibody targeting ErbB3) or placebo in postmenopausal women with locally advanced or metastatic ER+/PR+, HER2-negative breast cancer. Journal of Clinical Oncology. 32: 587-587. DOI: 10.1200/jco.2014.32.15_suppl.587  0.08
2014 Higgins MJ, Doyle C, Paepke S, Azaro A, Martin M, Semiglazov V, Smirnova I, Krasnozhon D, Manikhas A, Harb WA, Panasci LC, Pearlberg J, MacBeath G, Nering R, Goss PE, et al. A randomized, double-blind phase II trial of exemestane plus MM-121 (a monoclonal antibody targeting ErbB3) or placebo in postmenopausal women with locally advanced or metastatic ER+/PR+, HER2-negative breast cancer. Journal of Clinical Oncology. 32: 587-587. DOI: 10.1200/jco.2014.32.15_suppl.587  0.08
2014 Higgins MJ, Doyle C, Paepke S, Azaro A, Martin M, Semiglazov V, Smirnova I, Krasnozhon D, Manikhas A, Harb WA, Panasci LC, Pearlberg J, MacBeath G, Nering R, Goss PE, et al. A randomized, double-blind phase II trial of exemestane plus MM-121 (a monoclonal antibody targeting ErbB3) or placebo in postmenopausal women with locally advanced or metastatic ER+/PR+, HER2-negative breast cancer. Journal of Clinical Oncology. 32: 587-587. DOI: 10.1200/jco.2014.32.15_suppl.587  0.08
2014 Higgins MJ, Doyle C, Paepke S, Azaro A, Martin M, Semiglazov V, Smirnova I, Krasnozhon D, Manikhas A, Harb WA, Panasci LC, Pearlberg J, MacBeath G, Nering R, Goss PE, et al. A randomized, double-blind phase II trial of exemestane plus MM-121 (a monoclonal antibody targeting ErbB3) or placebo in postmenopausal women with locally advanced or metastatic ER+/PR+, HER2-negative breast cancer. Journal of Clinical Oncology. 32: 587-587. DOI: 10.1200/jco.2014.32.15_suppl.587  0.08
2014 Higgins MJ, Doyle C, Paepke S, Azaro A, Martin M, Semiglazov V, Smirnova I, Krasnozhon D, Manikhas A, Harb WA, Panasci LC, Pearlberg J, MacBeath G, Nering R, Goss PE, et al. A randomized, double-blind phase II trial of exemestane plus MM-121 (a monoclonal antibody targeting ErbB3) or placebo in postmenopausal women with locally advanced or metastatic ER+/PR+, HER2-negative breast cancer. Journal of Clinical Oncology. 32: 587-587. DOI: 10.1200/jco.2014.32.15_suppl.587  0.08
2014 Higgins MJ, Doyle C, Paepke S, Azaro A, Martin M, Semiglazov V, Smirnova I, Krasnozhon D, Manikhas A, Harb WA, Panasci LC, Pearlberg J, MacBeath G, Nering R, Goss PE, et al. A randomized, double-blind phase II trial of exemestane plus MM-121 (a monoclonal antibody targeting ErbB3) or placebo in postmenopausal women with locally advanced or metastatic ER+/PR+, HER2-negative breast cancer. Journal of Clinical Oncology. 32: 587-587. DOI: 10.1200/jco.2014.32.15_suppl.587  0.08
2014 Higgins MJ, Doyle C, Paepke S, Azaro A, Martin M, Semiglazov V, Smirnova I, Krasnozhon D, Manikhas A, Harb WA, Panasci LC, Pearlberg J, MacBeath G, Nering R, Goss PE, et al. A randomized, double-blind phase II trial of exemestane plus MM-121 (a monoclonal antibody targeting ErbB3) or placebo in postmenopausal women with locally advanced or metastatic ER+/PR+, HER2-negative breast cancer. Journal of Clinical Oncology. 32: 587-587. DOI: 10.1200/jco.2014.32.15_suppl.587  0.08
2018 Boudot A, Huang X, Murphy S, Appleman V, Xu H, Cheung NK, Macbeath G. ABP-100: A tetravalent bispecific T-cell engaging antibody for HER2+ solid tumors. Annals of Oncology : Official Journal of the European Society For Medical Oncology. 29: viii417-viii418. PMID 32137045 DOI: 10.1093/annonc/mdy288.043  0.069
2018 Boudot A, Huang X, Murphy S, Appleman V, Xu H, Cheung NK, Macbeath G. ABP-100: A tetravalent bispecific T-cell engaging antibody for HER2+ solid tumors. Annals of Oncology : Official Journal of the European Society For Medical Oncology. 29: viii417-viii418. PMID 32137045 DOI: 10.1093/annonc/mdy288.043  0.069
2018 Boudot A, Huang X, Murphy S, Appleman V, Xu H, Cheung NK, Macbeath G. ABP-100: A tetravalent bispecific T-cell engaging antibody for HER2+ solid tumors. Annals of Oncology : Official Journal of the European Society For Medical Oncology. 29: viii417-viii418. PMID 32137045 DOI: 10.1093/annonc/mdy288.043  0.069
1994 MacBeath G, Hilvert D. Monitoring catalytic activity by immunoassay: Implications for screening Journal of the American Chemical Society. 116: 6101-6106.  0.066
2021 Denlinger CS, Keedy VL, Moyo V, MacBeath G, Shapiro GI. Phase 1 dose escalation study of seribantumab (MM-121), an anti-HER3 monoclonal antibody, in patients with advanced solid tumors. Investigational New Drugs. PMID 34250553 DOI: 10.1007/s10637-021-01145-y  0.066
2021 Denlinger CS, Keedy VL, Moyo V, MacBeath G, Shapiro GI. Phase 1 dose escalation study of seribantumab (MM-121), an anti-HER3 monoclonal antibody, in patients with advanced solid tumors. Investigational New Drugs. PMID 34250553 DOI: 10.1007/s10637-021-01145-y  0.066
Hide low-probability matches.